Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have rapidly transformed the management of type 2 diabetes and obesity, with consistent benefits in weight reduction, glycaemic control, and cardiometabolic outcomes. Yet across trials, these agents are also... ...

请注册登录后继续浏览